Skip to main content
. Author manuscript; available in PMC: 2017 Jan 11.
Published in final edited form as: Cancer Cell. 2016 Jan 11;29(1):5–16. doi: 10.1016/j.ccell.2015.12.003

Table 1.

Summary of Myc, MycVD, and Myc/APOZ Engineered Tumors.

Number of Mice with Tumor / Total Number of Mice Tumor Latency (Days) Median Survival (Days) Pathology
Myc 25/25 16, 24, 26, 26, 27, 27, 28, 31, 32, 33, 33, 33, 34, 36, 38, 40, 40, 40, 41, 42, 43, 52, 56, 56, 59 34 LC/A, Myc/G3 MB
MycVD 6/13 61, 70, 77, 89, 109, 119 83 Neuroepithelial proliferation of unclassified type
Myc/ΔPOZ 10/10 22, 42, 44, 48, 49, 60, 61, 62, 69, 74 54.5 PNET-like tumor with LC/A; unclassified type

LC/A = Large cell/anaplastic, G3 MB = Group3 medulloblastoma, PNET = Primitive neuroectodermal tumor, median survival was calculated based on the number of mice that develop one tumor per animal.